Related Experiment Video
Updated: Apr 23, 2026
05:45
Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
4.4K
Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.
Armin Mooranian1, Rebecca Negrulj1, Nigel Chen-Tan2
1Biotechnology and Drug Development Research Laboratory School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, Perth, Western Australia, Australia.
Drug Design, Development and Therapy
|September 24, 2014
Summary
Novel microencapsulated probucol (PB) using sodium alginate (SA) shows promising structural properties for oral delivery in type 2 diabetes (T2D). These PB-SA microcapsules are stable and suitable for further clinical investigation.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Multicompartmental microcapsules are effective for oral drug delivery in type 2 diabetes (T2D).
- Probucol (PB), an antihyperlipidemic and antioxidant, has potential therapeutic benefits for T2D.
Purpose of the Study:
- To develop a novel microencapsulated formulation of Probucol (PB).
- To characterize the physicochemical properties of PB-loaded sodium alginate (PB-SA) microcapsules in vitro.
Main Methods:
- Microencapsulation of PB using a Büchi-based system with sodium alginate (SA) at a 1:30 ratio.
- Comprehensive in vitro characterization including morphology, size, thermal analysis (DSC), and spectral studies (FTIR).
Main Results:
- PB-SA microcapsules exhibited uniform morphology with an average diameter of 1 mm.
- Microcapsules demonstrated pseudoplastic-thixotropic rheological behavior.
- Differential scanning calorimetry and FTIR confirmed no chemical interactions and indicated good microcapsule stability.
Conclusions:
- The developed PB-SA microcapsules possess favorable structural and stability characteristics.
- These microcapsules show potential for the oral delivery of Probucol in type 2 diabetes.
- Further clinical studies are warranted to evaluate the efficacy and safety of PB in T2D.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:27Bioavailability Enhancement: Drug Permeability Enhancement
346
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
346
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
148
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148
01:30Modified-Release Drug Delivery Systems: Bioavailability
159
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
159
01:19Modified-Release Drug Delivery Systems: Overview
228
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
228
01:24Modified-Release Drug Delivery Systems: Site-Targeted
160
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160